NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Creating Markets for New Vaccines Part I: Rationale

Michael Kremer

NBER Working Paper No. 7716
Issued in May 2000
NBER Program(s):   HE   PE

Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to sell enough vaccine at a sufficient price to recoup their research expenditures. Enhancing markets for new vaccines could create incentives for vaccine research and increase accessibility of any vaccines developed. Private firms currently conduct little research on vaccines against malaria, tuberculosis, and the strains of HIV common in Africa. This is not only because these diseases primarily affect poor countries, but also because vaccines are subject to severe market failures. Government- directed research programs may be well-suited for basic research, but for the later, more applied states of research, committing to compensate successful private vaccine developers has important advantages. Under such programs, the public pays only if a successful vaccine is actually developed. This gives pharmaceutical firms and scientists strong incentives to self-select research projects that have a reasonable chance of leading to a vaccine. Committing to purchase vaccines and make them available to poor countries may also be attractive relative to other ways of rewarding vaccine developers.

download in pdf format
   (154 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (154 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w7716

Published: Creating Markets for New Vaccines - Part I: Rationale, Michael Kremer. in Innovation Policy and the Economy, Volume 1, Jaffe, Lerner, and Stern. 2001

Users who downloaded this paper also downloaded these:
Kremer Creating Markets for New Vaccines - Part I: Rationale
Nordhaus w11889 Life After Kyoto: Alternative Approaches to Global Warming
Kremer w7717 Creating Markets for New Vaccines Part II: Design Issues
Kremer Creating Markets for New Vaccines - Part II: Design Issues
Kremer and Snyder w9833 Why Are Drugs More Profitable Than Vaccines?
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us